NuGenerex Immuno-Oncology announced the Board of Directors who will help lead the company’s strategic plans to build a world-class immune-oncology organization. The Board is comprised of renowned leaders in the fields of oncology, biotechnology and pharmaceutical development, sales and marketing, operations, and finance. These highly regarded professionals will provide expertise and guidance to the NGIO management team as the company takes the final steps toward the listing of the NGIO shares on Nasdaq and the implementation of the NGIO strategic & operating plans. The board, whose biographies are presented herein, include internal members Joseph Moscato (Chairman), Anthony Crisci, Esq., CPA (Corporate Counsel & Chief Legal Officer) and Richard Purcell (Executive Vice President of R&D), as well as independent Directors Dr. Craig Eagle, MD, Dr. Marvin Hausman, MD, Carol Nacy, PhD, S. Gail Eckhardt, MD, Thomas Leonard, MPA, and Brian T. McGee. Joseph Moscato. Mr. Moscato is currently the Chief Executive Officer, President, and Chairman of the Board for Generex since January 2017. Mr. Moscato has over 30 years of experience in healthcare, sales and marketing, distribution management, and finance. Mr. Moscato brings his marketing and advertising acumen to drug discovery and diagnostic & treatment development and commercialization. Richard Purcell. Mr. Purcell currently is and has been the Executive Vice-President of Research & Drug Development for both NGIO and Generex since January 2017. Mr. Purcell has managed a consulting practice, DNA Healthlink Inc. advising emerging biopharmaceutical and technology companies on new business strategy, operations management, and clinical development of novel compounds. Anthony S. Crisci, Esq., C.P.A. Mr. Crisci is Generex Corporate Counsel and Chief Legal Officer of Generex and will serve in the same capacity at NGIO. He is an attorney and certified public accountant with over twenty (20) years of experience in tax, accounting, finance, corporate, healthcare and employee benefit matters. Mr. Crisci has built a stellar career as a business legal executive across a number of regulated industries. Dr. Craig Eagle, MD. Dr. Eagle is currently the Vice President of Medical Affairs Oncology for Genentech where he oversees the medical programs across the oncology portfolio. Prior to his current role, Dr. Eagle worked at Pfizer in several positions including as the oncology business lead in United Kingdom and Canada delivering significant business growth. Previously, Dr. Eagle was the global lead for Oncology Strategic Alliances and Partnerships based in New York at Pfizer Inc. and was involved in multiple deals on both the sell and buy side. Dr. Marvin S. Hausman, MD. Dr. Hausman is an Immunologist and Board-Certified Urological Surgeon with more than 30 years of drug research and development experience with various pharmaceutical companies, including Bristol-Myers International, Mead-Johnson Pharmaceutical Co., E.R. Squibb, Medco Research, and Axonyx. Dr. Hausman currently serves as Chairman of the Board & Chief Science and Technology Officer of Entia Biosciences Inc. Dr. Carol Nacy, PhD. Dr. Nacy is a founder and the Chief Executive Officer of Sequella Inc., a privately held pharmaceutical company that discovers and develops new and more effective treatments for life threatening infectious diseases. Previously, Dr. Nacy was Executive Vice President and Chief Scientific Officer at EntreMed Inc. from 1993 through its successful public offering in June 1996. S. Gail Eckhardt, MD. Dr. Eckhardt is a tenured professor at The University of Texas at Austin’s Dell Medical School where she is also the inaugural director of the Livestrong Cancer Institutes, chair of the Department of Oncology, and associate dean of cancer programs. She has been a faculty member at the institution since January of 2017. Prior to joining UT Austin, Eckhardt was at the University of Colorado School of Medicine where she was division head of medical oncology from 2006-2014, associate director for translational research at the University of Colorado Comprehensive Cancer Center and director of the Phase I Program and Fellowship. Thomas Leonard, MPA. Mr. Leonard had a long and successful career at Bristol Myers Squibb in pharmaceutical sales, marketing, and management across multiple segments of the healthcare delivery system, most recently as the Northeast Business Manager for Oncology. Mr. McGee serves as an independent Director of Generex since 2004. Mr. McGee has served as Chairman of the Generex Audit Committee and a member of the Generex Compensation and Corporate Governance and Nominating Committees. Mr. McGee has been a partner of Zeifmans LLP ("Zeifmans") since 1995.